Editas Medicine Inc (EDIT) Stock Forecast & Price Target
Editas Medicine Inc · NASDAQ
$2.62-0.07 (-2.43%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Editas Medicine Inc, 4 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $4.00 to $8.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $5.40 sits 107% above the current $2.62. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.28 next quarter toward $-0.94 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy480%
Hold120%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Editas Medicine Inc.
As of Jul, 4 of 5 firms rate EDIT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
EDIT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.28
Range $-0.33 – $-0.24 · 8 analysts · -0% YoY
Next period, 8 analysts expect Editas Medicine Inc to earn $-0.28 a share (range $-0.33 – $-0.24), versus $-0.28 a year earlier. Full-year consensus is $-1.00, growing to $-0.94 the year after.
REVENUE · NEXT QUARTER
$3.1M
Range $500.0K – $10.6M · 8 analysts · -59% YoY
Revenue is expected to reach $3.1M (range $500.0K – $10.6M), -58.6% year-over-year. Full-year consensus is $14.4M, rising to $14.7M next year.
Top analysts covering Editas Medicine Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on EDIT.
#1
Geulah Livshits
Chardan Capital · Rank #100
Buy
$4.00+53.0% to target
Overall win rate
44%
+ Follow
#2
Joel Beatty
Baird · Rank #111
Buy
$6.00+129.4% to target
Overall win rate
46%
+ Follow
#3
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Buy
$5.00+91.2% to target
Overall win rate
34%
+ Follow
#4
Yanan Zhu
Wells Fargo
Hold
$4.00+53.0% to target
Coverage
—
+ Follow
#5
Luca Issi
RBC Capital
Hold
$4.00+53.0% to target
Coverage
—
+ Follow
EDIT stock forecast FAQ
What is EDIT's average 12-month price target?+
The 5 analysts with a live target average $5.40 for Editas Medicine Inc over the next 12 months, ranging from a $8.00 high to a $4.00 low.
Is EDIT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 4 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for EDIT?+
The Street-high target is $8.00 (Jones Trading), and the Street-low is $4.00 (Chardan Capital). The average of all 5 active targets is $5.40.
How many Wall Street analysts cover EDIT?+
5 analysts have an active rating on Editas Medicine Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering EDIT?+
Among analysts who currently cover EDIT, Geulah Livshits of Chardan Capital has the strongest overall Quantellect track record (Rank #100). Their current call is Buy with a $4.00 target.
What is Editas Medicine Inc's projected EPS for next quarter?+
The consensus estimate is $-0.28 per share (range $-0.33 – $-0.24) across 8 analysts. Full-year EPS is projected at $-1.00, rising to $-0.94 the following year.
How much revenue is Editas Medicine Inc expected to report next quarter?+
Consensus revenue is $3.1M (range $500.0K – $10.6M). Full-year revenue is projected at $14.4M, growing to $14.7M next year.
Have analysts been upgrading or downgrading EDIT lately?+
As of Jul, 4 of 5 firms rate EDIT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their EDIT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
